総医研ホールディングス has entered into an agreement with Sichuan Kelun Pharmaceutical Group of China to establish a framework for joint research on novel functional materials. The two companies are expected to promote joint research on material development going forward.
総医研ホールディングス has entered into an agreement with a group company of Sichuan Kelun Pharmaceutical Group, a major Chinese pharmaceutical company, establishing a framework for joint research on novel functional materials.
The agreement formally establishes a cooperative framework between the two companies and aims to define the details of joint research, including material development and evaluation and the exchange of technical information.
Going forward, practical arrangements are expected to be made regarding the functional materials to be covered by the joint research, research schedules and the treatment of intellectual property. Attention will focus on the potential commercialization of the research results and their possible fields of application.
Through the agreement, 総医研ホールディングス has indicated a policy of strengthening its use of global research resources and advancing the development of novel materials.